Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. Crossover from the chemotherapy group to the pembrolizumab group was permitted in the event of disease progression. The primary end point, progression-free survival, was assessed by means of blinded, independent, central radiologic review. Secondary end points were overall survival, objective response rate, and safety. RESULTS: Median progression-free survival was 10.3 months (95% confidence interval [CI], 6.7 to not reached) in the pembrolizumab group versus 6.0 months (95% CI, 4.2 to 6.2) in the chemotherapy group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.37 to 0.68; P<0.001). The estimated rate of overall survival at 6 months was 80.2% in the pembrolizumab group versus 72.4% in the chemotherapy group (hazard ratio for death, 0.60; 95% CI, 0.41 to 0.89; P=0.005). The response rate was higher in the pembrolizumab group than in the chemotherapy group (44.8% vs. 27.8%), the median duration of response was longer (not reached [range, 1.9+ to 14.5+ months] vs. 6.3 months [range, 2.1+ to 12.6+]), and treatment-related adverse events of any grade were less frequent (occurring in 73.4% vs. 90.0% of patients), as were grade 3, 4, or 5 treatment-related adverse events (26.6% vs. 53.3%). CONCLUSIONS: In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. (Funded by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, ICIs are also associated with frequent and potentially organ- or life-threatening immune-related adverse events (irAEs), which generally mimic autoimmune or inflammatory conditions”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“indeed, up to 90% of patients treated with ipilimumab and up to 70% of those treated with PD-1/PD-L1 antibodies experience at least one irAE).3,4”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial trials on anti-PD-1 and anti-PD-L1 inhibitors reported a significant association between pre-treatment intratumoral PD-L1 expression and response to treatment in a variety of tumor types including melanoma and NSCLC”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reck et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Research works printed but not linked: 1
- Xiao HQ, 2016, Onco Targets Ther, 9, 1471
Cited by
Items 601–700 of 1,054
Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?
Hilmi, M., Jouinot, A., Burns, R. G., Pigneur, F., Mounier, R., Gondin, J., Neuzillet, C., & Goldwasser, F. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.003 · Cited by 164
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
Crinò, L., Bronte, G., Bidoli, P., Cravero, P., Minenza, E., Cortesi, E., Garassino, M. C., Proto, C., Cappuzzo, F., Grossi, F., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.025 · Cited by 162
Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N., & Neilan, T. G. (2021) · JACC: CardioOncology · doi:10.1016/j.jaccao.2020.11.012 · Cited by 141
Yin, Z., Yu, M., Ma, T., Zhang, C., Huang, S., Karimzadeh, M. R., Momtazi‐Borojeni, A. A., & Chen, S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001698 · Cited by 162
Wang, M., Zhai, X., Li, J., Guan, J., Xu, S., Li, Y., & Zhu, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670391 · Cited by 162
Ricciuti, B., Jones, G., Severgnini, M., Alessi, J. V., Recondo, G., Lawrence, M., Forshew, T., Lydon, C., Nishino, M., Cheng, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001504 · Cited by 161
Mushti, S. L., Mulkey, F., & Sridhara, R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1902 · Cited by 161
Applications and strategies in nanodiagnosis and nanotherapy in lung cancer
Woodman, C., Vundu, G., George, A., & Wilson, C. M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.009 · Cited by 161
Su, Q., Zhu, E. C., Wu, J.-B., Li, T., Hou, Y.-L., Wang, D.-Y., & Gao, Z.-H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00108 · Cited by 161
Rosière, R., Van Woensel, M., Gelbcke, M., Mathieu, V., Hecq, J., Mathivet, T., Vermeersch, M., Van Antwerpen, P., Amighi, K., & Wauthoz, N. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00846 · Cited by 161
An update on the immune landscape in lung and head and neck cancers
Carlisle, J. W., Steuer, C. E., Owonikoko, T. K., & Saba, N. F. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21630 · Cited by 161
Sun, X., Roudi, R., Dai, T., Chen, S., Fan, B., Li, H., Zhou, Y., Zhou, M., Zhu, B., Yin, C., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5701-6 · Cited by 160
Nanomedicine‐Boosting Tumor Immunogenicity for Enhanced Immunotherapy
Huang, J., Yang, B., Peng, Y., Huang, J., Wong, S. H. D., Bian, L., Zhu, K., Shuai, X., & Han, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011171 · Cited by 157
Spigel, D. R., Chaft, J. E., Gettinger, S., Chao, B. H., Dirix, L., Schmid, P., Chow, L. Q. M., Hicks, R. J., Leon, L., Fredrickson, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.004 · Cited by 159
Haffner, M. C., Guner, G., Taheri, D., Netto, G. J., Palsgrove, D. N., Zheng, Q., Guedes, L. B., Kim, K., Tsai, H., Esopi, D. M., et al. (2018) · The American Journal of Pathology · doi:10.1016/j.ajpath.2018.02.014 · Cited by 159
Mo, H., Huang, J., Xu, J., Chen, X., Wu, D., Qu, D., Wang, X., Lan, B., Wang, X., Xu, J., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0100-3 · Cited by 154
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 160
Kimbara, S., Fujiwara, Y., Iwama, S., Ohashi, K., Kuchiba, A., Arima, H., Yamazaki, N., Kitano, S., Yamamoto, N., & Ohe, Y. (2018) · Cancer Science · doi:10.1111/cas.13800 · Cited by 158
“Presence of TPOAb alone (≥16 IU/mL) 16 (10) 16 (46) 0 (0)”
Li, Y., Yan, H., Xu, X., Liu, H., Wu, C., & Zhao, L. (2019) · Oncology Letters · doi:10.3892/ol.2019.11066 · Cited by 158
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
Jia, Q., Wang, J., He, N., He, J., & Zhu, B. (2019) · JCI Insight · doi:10.1172/jci.insight.127901 · Cited by 158
Dietel, M., Savelov, N., Salanova, R., Micke, P., Bigras, G., Hida, T., Antunez, J., Guldhammer Skov, B., Hutarew, G., Sua, L. F., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.012 · Cited by 158
Costa, R. L. B., & Czerniecki, B. J. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0153-3 · Cited by 158
Anti-TIGIT therapies for solid tumors: a systematic review
Rousseau, A., Parisi, C., & Barlesi, F. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101184 · Cited by 158
Synthetic lethality-mediated precision oncology via the tumor transcriptome
Lee, J. S., Nair, N. U., Dinstag, G., Chapman, L., Chung, Y., Wang, K., Sinha, S., Cha, H., Kim, D., Schperberg, A. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.030 · Cited by 158
Quatrini, L., Mariotti, F. R., Munari, E., Tumino, N., Vacca, P., & Moretta, L. (2020) · Cancers · doi:10.3390/cancers12113285 · Cited by 158
Hirano, H., & Kato, K. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz034 · Cited by 158
Brueckl, W. M., Ficker, J. H., & Zeitler, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07690-8 · Cited by 158
Skov, B. G., & Skov, T. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000540 · Cited by 158
Owen, D. H., Wei, L., Bertino, E. M., Edd, T., Villalona-Calero, M. A., He, K., Shields, P. G., Carbone, D. P., & Otterson, G. A. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.08.008 · Cited by 145
Molecular profiles of small cell lung cancer subtypes: Therapeutic implications
Solta, A., Megyesfalvi, Z., Bárány, N., Valkó, Z., Bugyik, E., Lang, C., Ferencz, B., Paku, S., Lantos, A., Fillinger, J., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.02.004 · Cited by 158
Development of therapeutic antibodies for the treatment of diseases
Wang, Z., Wang, G., Lu, H., Li, H., Tang, M., & Tong, A. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00100-4 · Cited by 157
Combining chemotherapy with PD-1 blockade in NSCLC
Mathew, M., Enzler, T., Shu, C. A., & Rizvi, N. A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.003 · Cited by 145
Tunali, I., Gray, J. E., Qi, J., Abdalah, M., Jeong, D. K., Guvenis, A., Gillies, R. J., & Schabath, M. B. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.010 · Cited by 144
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
Akamatsu, H., Ninomiya, K., Kenmotsu, H., Morise, M., Daga, H., Goto, Y., Kozuki, T., Miura, S., Sasaki, T., Tamiya, A., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01431-z · Cited by 156
Combination therapy with PD-1 or PD-L1 inhibitors for cancer
Hayashi, H., & Nakagawa, K. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01548-1 · Cited by 156
Zhou, J., Wu, Z., Hu, J., Yang, D., Chen, X., Wang, Q., Liu, J., Dou, M., Peng, W., Wu, Y., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc1204 · Cited by 156
Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy
Saito, M., Suzuki, H. Y., Kono, K., Takenoshita, S., & Kohno, T. (2017) · Surgery Today · doi:10.1007/s00595-017-1497-7 · Cited by 155
Groisberg, R., Hong, D. S., Behrang, A., Hess, K., Janku, F., Piha-Paul, S., Naing, A., Fu, S., Benjamin, R., Patel, S., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0301-y · Cited by 148
Sears, C. R., Peikert, T., Possick, J. D., Naidoo, J., Nishino, M., Patel, S. P., Camus, P., Gaga, M., Garon, E. B., Gould, M. K., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201906-1202st · Cited by 141
Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice
Aggarwal, C., Rolfo, C. D., Oxnard, G. R., Gray, J. E., Sholl, L. M., & Gandara, D. R. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0423-x · Cited by 155
Hummel, H.-D., Kufer, P., Grüllich, C., Seggewiss-Bernhardt, R., Deschler-Baier, B., Chatterjee, M., Goebeler, M.-E., Miller, K., de Santis, M., Loidl, W., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0256 · Cited by 154
Engineering nanoparticle strategies for effective cancer immunotherapy
Yoon, H. Y., Selvan, S. T., Yang, Y., Kim, M. J., Yi, D. K., Kwon, I. C., & Kim, K. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.036 · Cited by 148
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Garris, C. S., & Luke, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1321 · Cited by 137
Waterhouse, D. M., Lam, J., Betts, K. A., Yin, L., Gao, S. W., Yuan, Y., Hartman, J., Rao, S. A., Lubinga, S. J., & Stenehjem, D. D. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.04.007 · Cited by 155
Self-citationTowards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
Wang, Q., & Wu, X. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.03.015 · Cited by 154
The intimate relationship between gut microbiota and cancer immunotherapy
Elkrief, A., Derosa, L., Zitvogel, L., Kroemer, G., & Routy, B. (2019) · Gut Microbes · doi:10.1080/19490976.2018.1527167 · Cited by 141
Nixon, N. A., Blais, N., Ernst, S., Kollmannsberger, C., Bebb, G. D., Butler, M. O., Smylie, M., & Verma, S. (2018) · Current Oncology · doi:10.3747/co.25.3840 · Cited by 153
Fox, C. P., Civallero, M., Ko, Y. H., Manni, M., Skrypets, T., Pileri, S. A., Kim, S. J., Cabrera, M. E., Shustov, A. R., CHIATTONE, C. S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30283-2 · Cited by 153
Facchinetti, F., Mazzaschi, G., Barbieri, F., Passiglia, F., Mazzoni, F., Berardi, R., Proto, C., Cecere, F. L., Pilotto, S., Scotti, V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.023 · Cited by 153
Ma, K., Lu, Y., Jiang, S., Tang, J., Li, X., & Zhang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01430 · Cited by 153
Mishima, S., Kawazoe, A., Nakamura, Y., Sasaki, A., Kotani, D., Kuboki, Y., Bando, H., Kojima, T., Doi, T., Ohtsu, A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0514-3 · Cited by 152
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors
Lauko, A. J., Lo, A., Ahluwalia, M. S., & Lathia, J. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.014 · Cited by 155
Immune Checkpoint Inhibitor–Induced Cardiotoxicity: A Systematic Review and Meta-Analysis
Nielsen, D. L., Juhl, C. B., Nielsen, O. H., Chen, I. M., & Herrmann, J. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.3065 · Cited by 155
Huang, M., Lou, Y., Pellissier, J. M., Burke, T. A., Liu, F. X., Xu, R., & Velcheti, V. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0527-z · Cited by 151
Jiang, Z., Yang, Y., Yang, Y., Zhang, Y., Yue, Z., Pan, Z., & Ren, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.129 · Cited by 151
Kordbacheh, T., Honeychurch, J., Blackhall, F. H., Finn, C. F., & Illidge, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx790 · Cited by 152
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
Offin, M. D., Guo, R., Wu, S. L., Sabari, J. K., Land, J. D., Ni, A., Montecalvo, J., Halpenny, D. F., Buie, L. W., Pak, T., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00386 · Cited by 151
Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion
Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Kelly, M. J., Michie, J., Pijpers, L., Johnstone, R. W., Kearney, C. J., & Oliaro, J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.017 · Cited by 141
Wang, X., Li, X., Wei, X., Jiang, H., Lan, C., Yang, S., Wang, H., Yang, Y., Tian, C., Xu, Z., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0144-8 · Cited by 151
PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
Yang, T., Kong, Z., & Ma, W. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1782692 · Cited by 152
Chow, A. T., Uddin, F. Z., Liu, M., Dobrin, A., Nabet, B. Y., Mangarin, L. M. B., Lavin, Y., Rizvi, H. A., Tischfield, S. E., Quintanal-Villalonga, À., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.12.001 · Cited by 153
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.002 · Cited by 151
Immune checkpoint blockade therapy
Wieder, T., Eigentler, T., Brenner, E., & Röcken, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.042 · Cited by 152
Soyano, A. E., Dholaria, B., Marin-Acevedo, J. A., Diehl, N. N., Hodge, D. O., Luo, Y., Manochakian, R., Chumsri, S., Adjei, A. A., Knutson, K. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0447-2 · Cited by 150
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Gray, J. E., Saltos, A., Tanvetyanon, T., Haura, E. B., Creelan, B., Antonia, S. J., Shafique, M., Zheng, H., Dai, W., Saller, J. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1305 · Cited by 141
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC
Lin, S. H., Lin, Y. H., Yao, L., Kalhor, N., Carter, B. W., Altan, M., Blumenschein, G. R., Byers, L. A., Fossella, F. V., Gibbons, D. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.024 · Cited by 150
Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
Šutić, M., Vukić, A., Baranašić, J., Försti, A., Džubur, F., Samaržija, M., Jakopović, M., Brčić, L., & Knežević, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111102 · Cited by 150
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L., Szeliga, W., Herbst, R., Harms, P. W., Fecher, L. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120803 · Cited by 141
Núñez, N. G., Berner, F., Friebel, E., Unger, S., Wyss, N., Gómez, J. M. M., Purde, M.-T., Niederer, R., Porsch, M., Lichtensteiger, C., et al. (2023) · Med · doi:10.1016/j.medj.2022.12.007 · Cited by 150
Lee, K. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.001 · Cited by 150
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non–Small Cell Lung Cancer
Cooper, W. A., Russell, P. A., Cherian, M., Duhig, E. E., Godbolt, D., Jessup, P. J., Khoo, C., Leslie, C., Mahar, A., Moffat, D. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0151 · Cited by 137
Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer
Chanier, T., & Chames, P. (2019) · Antibodies · doi:10.3390/antib8010013 · Cited by 150
YY1 regulates cancer cell immune resistance by modulating PD-L1 expression
Hays, E., & Bonavida, B. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.04.001 · Cited by 152
Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients
Lin, M., Luo, H., Liang, S., Chen, J., Liu, A., Niu, L., & Jiang, Y. (2020) · Journal of Clinical Investigation · doi:10.1172/jci132712 · Cited by 149
Pasello, G., Pavan, A., Attili, I., Bortolami, A., Bonanno, L., Menis, J., Conte, P., & Guarneri, V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102031 · Cited by 149
Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 149
Mark, N. M., Kargl, J., Busch, S., Yang, G. H. Y., Metz, H. E., Zhang, H., Hubbard, J. J., Pipavath, S. N. J., Madtes, D. K., & Houghton, A. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201704-0795oc · Cited by 148
Immune checkpoint inhibitors win the 2018 Nobel Prize
Huang, P., & Chang, J. W. (2019) · Biomedical Journal · doi:10.1016/j.bj.2019.09.002 · Cited by 150
The metabolic landscape of lung cancer: New insights in a disturbed glucose metabolism
Vanhove, K., Graulus, G.-J., Mesotten, L., Thomeer, M., Derveaux, E., Noben, J.-P., Guedens, W., & Adriaensens, P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01215 · Cited by 147
“Mutations in IDH1 and IDH2 are found in 1% of NSCLC and result in the conversion of α-KG to 2-hydroxyglutarate (62).”
BackgroundInfluentialwritten on behalf of the AME Academic Lung Cancer Cooperation Group, Hu, Y., Zhang, Q., Li, H., Michot, J., Liu, H., Zhan, P., Lv, T., & Song, Y. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.12.10 · Cited by 147
Zer, A., Sung, M. R., Walia, P., Khoja, L., Maganti, M., Labbe, C., Shepherd, F. A., Bradbury, P. A., Feld, R., Liu, G., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.008 · Cited by 134
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 135
Sperduto, P. W., De, B. S., Li, J., Carpenter, D. J., Kirkpatrick, J. P., Milligan, M., Shih, H. A., Kütük, T., Kotecha, R. R., Higaki, H., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.03.020 · Cited by 146
Recent Advances and Challenges in Cancer Immunotherapy
Peterson, C. M., Denlinger, N., & Yang, Y. (2022) · Cancers · doi:10.3390/cancers14163972 · Cited by 146
Current status of immune checkpoint inhibition in early-stage NSCLC
Vansteenkiste, J., Wauters, E., Reymen, B. J. T., Ackermann, C. J., Peters, S., & Ruysscher, D. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz175 · Cited by 145
Phase 2 study of pembrolizumab in patients with advanced rare cancers
Naing, A., Meric‐Bernstam, F., Stephen, B., Karp, D. D., Hajjar, J., Rodon, J. A., Piha-Paul, S. A., Colen, R. R., Jiménez, C., Raghav, K. P. S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000347 · Cited by 146
Matsubara, E., Yano, H., Pan, C., Komohara, Y., Fujiwara, Y., Zhao, S., Shinchi, Y., Kurotaki, D., & Suzuki, M. (2023) · Cancers · doi:10.3390/cancers15082250 · Cited by 145
Clinical assessment of immune-related adverse events
Sosa, A., Lopez Cadena, E., Simon Olive, C., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918764628 · Cited by 132
Kanai, O., Kim, Y. H., Demura, Y., Kanai, M., Ito, T., Fujita, K., Yoshida, H., Akai, M., Mio, T., & Hirai, T. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12759 · Cited by 144
Mechanisms of Resistance to Immune Checkpoint Blockade
Liu, D., Jenkins, R. W., & Sullivan, R. J. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0389-y · Cited by 130
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression
Mahoney, K. M., Shukla, S. A., Patsoukis, N., Chaudhri, A., Browne, E. P., Arazi, A., Eisenhaure, T., Pendergraft, W. F., Hua, P., Pham, H. C., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2282-1 · Cited by 144
Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
Zhong, X., Zhang, H.-T., Zhu, Y., Liang, Y., Yuan, Z., Li, J., Li, X., Li, X., Jia, Y., Tian, H., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1141-9 · Cited by 144
Galvano, A., Gristina, V., Malapelle, U., Pisapia, P., Pepe, F., Barraco, N., Castiglia, M., Perez, A., Rolfo, C. D., Troncone, G., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100124 · Cited by 144
de Rodas, M. L., Nagineni, V., Ravi, A., Datar, I. J., Mino-Kenudson, M. A., Corredor, G., Barrera, C., Behlman, L., Rimm, D. L., Herbst, R. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004440 · Cited by 145
Prospects for combining immune checkpoint blockade with PARP inhibition
Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143
“The level of PD-L1 is a vital biomarker predicting the efficacy of anti-PD-1/PD-L1 efficacy [86, 113].”
BackgroundIncorvaia, L., Fanale, D., Badalamenti, G., Barraco, N., Bono, M., Corsini, L. R., Galvano, A., Gristina, V., Listì, A., Vieni, S., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01057-7 · Cited by 144
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Ma, W., Xue, R., Zhu, Z. G., Farrukh, H., Song, W., Li, T., Zheng, L., & Pan, C.-X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00372-8 · Cited by 145
Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
Sen, T., Gay, C. M., & Byers, L. A. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.02.03 · Cited by 142
Wen, W. X., & Leong, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215381 · Cited by 142
Metadata
- Authors
- Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., & Brahmer, J. R.
- Affiliations
- The University of Sydney (AU)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-10
- Volume
- 375
- Issue
- 19
- Pages
- 1823-1833
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2527905628
- Cited by
- 10,089
- References
- 54
- Citations by year
- 2026: 584 · 2025: 750 · 2024: 913 · 2023: 1012 · 2022: 1108 · 2021: 1321 · 2020: 1324 · 2019: 1154 · 2018: 1132 · 2017: 724 · 2016: 46
- FWCI
- 548.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- pembrolizumab, PD-L1-positive non-small cell lung cancer, PD-1 inhibitors, immune checkpoint inhibitors, platinum-based chemotherapy, progression-free survival, overall survival, objective response rate, treatment-related adverse events, EGFR wild-type, immunotherapy versus chemotherapy, duration of response
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Platinum Compounds, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.